OptumRx WatchList Includes Rare Disease Drugs, Potential Price Disruptors
Executive Summary
Pharmacy benefit manager’s new pipeline report offers insight into upcoming drugs of concern to payers.
You may also be interested in...
Rybelsus, Other Treatment Improvements For Chronic Disease Have OptumRx’s Attention
UnitedHealthcare’s pharmacy benefit manager highlights potential cost pressures from upcoming novel or improved treatments for diabetes, wet AMD, HIV and migraine, as well as luspatercept for beta thalassemia, in its latest pipeline report.
It's Official: Novartis SMA Gene Therapy Zolgensma Is World's Most Expensive Drug
The total cost of Zolgensma is more than $2m – in line with estimates – or $425,000 annually for five years if payers choose an annuity-like payment plan. Novartis is also negotiating value-based reimbursement agreements for infants treated with the one-time infusion.
Pfizer Wins Tafamidis Approval; Now It Will Need To Build The Market
Tafamidis was approved by FDA in two formulations that will be marketed as Vyndaqel and Vyndamax for the treatment of transthyretin amyloid cardiomyopathy.